Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8985342 | 0.91 | MAPK14 (0.83) | MAPK14PTGS1PTGS2 | |
| SCHEMBL17542551 | 0.87 | MAPK14 (1.00) | MAPK14PTGS1PTGS2 | |
| SCHEMBL17552011 | 0.85 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL17542503 | 0.82 | MAPK14 (1.00) | MAPK14PTGS1PTGS2 | |
| SCHEMBL19349035 | 0.81 | MAPK14 (0.78) | MAPK14 | |
| SCHEMBL5250495 | 0.81 | MAPK14 (1.00) | MAPK14PTGS1PTGS2 | |
| SCHEMBL8985362 | 0.81 | OPRD1 (0.71) | MAPK14PTGS1PTGS2 | |
| SCHEMBL8985510 | 0.81 | MAPK14 (0.67) | MAPK14PTGS1PTGS2 | |
| SCHEMBL8985288 | 0.81 | MAPK14 (0.67) | MAPK14PTGS1PTGS2 | |
| SCHEMBL19367813 | 0.80 | MAPK14 (0.80) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186245-B1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2021-06-23 | — | — | EP | disclosed |
| EP-3186245-B1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2021-06-23 | — | — | EP | disclosed |
| CN-107074831-B | MAPK inhibitors | 永辉药业 | 2020-12-08 | — | — | CN | disclosed |
| US-20180289684-A1 | MAPK INHIBITORS | EverBrilliant Pharma Pty Ltd (AU) | 2018-10-11 | — | — | US | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170266173-A1 | MAPK INHIBITORS | EVERBRILLIANT PHARMA PTY LTD. (AU) | 2017-09-21 | — | — | US | disclosed |
| CN-107074831-A | Mapk inhibitors | 王炳辉 | 2017-08-18 | — | — | CN | disclosed |
| EP-3186245-A1 | MAPK INHIBITORS | Wang, Bing Hui (AU) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016029263-A1 | MAPK INHIBITORS | WANG BING HUI (AU) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016029263-A1 | MAPK INHIBITORS | WANG BING HUI (AU) | 2016-03-03 | — | — | WO | disclosed |
| EP-1361225-B1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | SANKYO CO (JP) | 2007-11-07 | — | — | EP | disclosed |
| US-7091352-B2 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1361225-A1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | Sankyo Company, Limited (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266173-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | MAPK14 13/4885PTGS1 116/4885PTGS2 221/4885 |
| US-20040147525-A1 | Compounds substituted with bicyclic amino groups | IL2, IL1B, IL4I1 | MAPK14 1355/4885PTGS1 31/4885PTGS2 90/4885 |
| US-20180289684-A1 | MAPK INHIBITORS | MAPK1, MAPK4, MAPK3 | MAPK14 13/4885PTGS1 116/4885PTGS2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.